Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Mark E. Davis, Ph.D.
Mark E. Davis, Ph.D.

Affiliation(s):

Warren and Katharine Schlinger Professor of Chemical Engineering, California Institute of Technology
Member, JCCC Cancer Nanotechnology Program Area

Contact Information:

Phone:
(626) 395-4251
Email:

Scientific Interest(s):

Dr. Mark Davis is interested in drug delivery and nanotechnology.

Selected Cancer-Related Publications:

Choi CH, Zuckerman JE, Webster P, Davis ME. Targeting kidney mesangium by nanoparticles of defined size. Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6656-61. Epub 2011 Apr 4.

Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010 Apr 15;464(7291):1067-70. Epub 2010 Mar 21.

Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm. 2009 May-Jun;6(3):659-68.

Choi CH, Alabi CA, Webster P, Davis ME. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1235-40. Epub 2009 Dec 29.

Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008 Sep;7(9):771-82.